Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Network Genomic Medicine \(NGM\)"" wg kryterium: Autor


Wyświetlanie 1-3 z 3
Tytuł :
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[ F]fluoroethyl)-L-tyrosine PET.
Autorzy :
Abdulla DSY; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Scheffler M; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Brandes V; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Ruge M; Center for Integrated Oncology Köln, Bonn, Germany; Department of Stereotaxy and Functional Neurosurgery, University Hospital of Cologne, Cologne, Germany.
Kunze S; Center for Integrated Oncology Köln, Bonn, Germany; Department of Radiotherapy, University Hospital of Cologne, Cologne, Germany.
Merkelbach-Bruse S; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany; Department of Pathology, University Hospital of Cologne, Cologne, Germany.
Nogova L; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Michels S; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Fischer R; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Riedel R; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
Büttner R; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany; Department of Pathology, University Hospital of Cologne, Cologne, Germany.
Persigehl T; Center for Integrated Oncology Köln, Bonn, Germany; Department of Radiology, University Hospital of Cologne, Cologne, Germany.
Grau S; Center for Integrated Oncology Köln, Bonn, Germany; Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany.
Galldiks N; Center for Integrated Oncology Köln, Bonn, Germany; Department of Neurology, University Hospital of Cologne, Cologne, Germany; Institute of Neuroscience and Medicine, Research Center Juelich, Juelich, Germany.
Drzezga A; Center for Integrated Oncology Köln, Bonn, Germany; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.
Kobe C; Center for Integrated Oncology Köln, Bonn, Germany; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.
Wolf J; Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany. Electronic address: .
Pokaż więcej
Źródło :
Clinical lung cancer [Clin Lung Cancer] 2019 Mar; Vol. 20 (2), pp. e148-e151. Date of Electronic Publication: 2018 Nov 05.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Brain Neoplasms/*diagnosis
Carcinoma, Non-Small-Cell Lung/*diagnosis
Erlotinib Hydrochloride/*therapeutic use
Lung Neoplasms/*diagnosis
Tyrosine/*analogs & derivatives
Adult ; Brain Neoplasms/drug therapy ; Brain Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/secondary ; ErbB Receptors/genetics ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Mutation/genetics ; Positron-Emission Tomography
Czasopismo naukowe
Tytuł :
Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center.
Autorzy :
Kron F; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
Kostenko A; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
Scheffler M; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
Müller D; Institute of Health Economics and Clinical Epidemiology, University of Cologne, Germany.
Glossmann JP; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
Fischer R; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
Michels S; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
Nogova L; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
Hallek M; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Zander T; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Wolf J; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany. Electronic address: .
Pokaż więcej
Źródło :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2017 Jun; Vol. 108, pp. 134-139. Date of Electronic Publication: 2017 Mar 30.
Typ publikacji :
Journal Article
MeSH Terms :
Costs and Cost Analysis*
Lung Neoplasms/*epidemiology
Aged ; Cancer Care Facilities ; Clinical Trials as Topic ; Female ; Germany/epidemiology ; Humans ; Lung Neoplasms/diagnosis ; Male ; Middle Aged ; Neoplasm Staging ; Retrospective Studies ; Standard of Care
Czasopismo naukowe
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies